Complement-Based Drug Development Summit leaderboard
  • Thursday, October 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 29

Author

Pharma Journalist 9091 posts 0 comments

Gilead, WHO Renew Kala-Azar Elimination Partnership

May 22, 2026
Gilead Sciences has renewed its collaboration with the World Health Organization (WHO) for another five years, strengthening efforts to eliminate visceral leishmaniasis (VL), commonly…
Read More...

J&J, Abu Dhabi Launch Global Surgical AI Network

May 21, 2026
Johnson & Johnson has partnered with the Department of Health – Abu Dhabi to launch a global initiative aimed at building an open surgical intelligence network, positioning Abu…
Read More...

Regeneron Reports Promising Amyloidosis Trial Results

May 21, 2026
Regeneron Pharmaceuticals reported encouraging early-stage results from a Phase 1/2 clinical trial evaluating Lynozyfic (linvoseltamab) in patients with relapsed or treatment-resistant…
Read More...

Lilly Acquires Engage to Expand Genetic Medicine Pipeline

May 21, 2026
Eli Lilly and Company has acquired preclinical biotechnology company Engage Biologics Inc. in a deal worth up to $202 million, strengthening the drugmaker’s ambitions in next-generation…
Read More...

SERB Acquires Idefirix Rights in Europe and MENA

May 21, 2026
SERB Pharmaceuticals and Hansa Biopharma have entered into an agreement under which SERB will acquire exclusive development and commercialization rights to Idefirix (imlifidase) across…
Read More...

QIAGEN, NVIDIA Expand AI Drug Discovery Collaboration

May 21, 2026
QIAGEN announced a new collaboration with NVIDIA aimed at integrating accelerated computing and artificial intelligence into drug discovery workflows, a move the company says could help…
Read More...

Merck Phase 3 Trial Shows Promise in Endometrial Cancer

May 20, 2026
Global pharmaceutical company Merck & Co. has announced positive pivotal Phase 3 results for sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug…
Read More...

Takeda Faces $885 Million AMITIZA Antitrust Verdict

May 20, 2026
Takeda Pharmaceutical Company said a U.S. federal jury has returned a verdict against the company in long-running antitrust litigation involving constipation drug AMITIZA, awarding…
Read More...

Regeneron, Parabilis Partner on Novel Cancer Drug Platform

May 19, 2026
Regeneron Pharmaceuticals has entered into a strategic research collaboration with Parabilis Medicines to discover and develop a new class of therapeutics designed to target…
Read More...

FDA Grants Breakthrough Status to VERTANICAL Pain Drug

May 19, 2026
VERTANICAL said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, the company’s investigational non-opioid treatment for chronic low back…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.